Gene Therapy for Age-related Macular Degeneration-A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the Gene Therapy Molecules For Age-Related Macular Degeneration in the development and pre-clinical stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.

Market research analysts have predicted that with the introduction of techniques such as fluorescein angiography, the global age-related macular degeneration market Will Register A CAGR Of More Than 7% by 2020.

Download PDF Sample of Gene Therapy for Age-related Macular Degeneration Market Report@ http://orbisresearch.com/contacts/request-sample/2099670

The global Gene Therapy for Age-related Macular Degeneration report is a gem in terms of the information on offer in the report which should be of great importance for the customers in the Gene Therapy for Age-related Macular Degeneration across the globe. The well-compiled report enhances the customers’ abilities in making sound decisions for their growth in the global Gene Therapy for Age-related Macular Degeneration.

The comprehensive report covers all bases of information in the Gene Therapy for Age-related Macular Degeneration which includes multiple parameters such as market segmentation, major players, regions, drivers-challenges and trends, and SWOT analysis which is the core for any good report. The global Gene Therapy for Age-related Macular Degeneration report is compiled by a team of top subject experts and research specialists who ensure the report for the global Gene Therapy for Age-related Macular Degeneration is unique and accurate.

The global Gene Therapy for Age-related Macular Degeneration report covers key information of value for the customers as follows:
• Gene Therapy for Age-related Macular Degeneration overview
• Key players in Gene Therapy for Age-related Macular Degeneration
• Market competition by Players
• Statistics of production, revenue, and capacity, drilled down by the region
• Statistics of consumption, exports, and imports, segmented by the region
• Global Gene Therapy for Age-related Macular Degeneration application analysis, cost analysis, and other important data.

Browse Full Report with TOC: http://orbisresearch.com/reports/index/gene-therapy-for-age-related-macular-degeneration-a-pipeline-analysis-report

PART 1: GENE THERAPY FOR MUCOPOLYSACCHARIDOSES: AN INSIGHT
• Introduction
• MAJOR REGULATORY AUTHORITIES
• US
• Europe
• Japan
• Australia
• China

PART 2: COMPARATIVE ANALYSIS
• Mid-stage molecules (Phase I/II), 2017
• Early-stage molecules (pre-IND and IND), 2017
• Pre-clinical stage molecules, 2017
• Suspended molecule, 2017

Key questions answered in the report include
• What are the different stages of the pipeline molecules under investigation?
• What are the gene therapy molecules in the various development stages for age-related macular degeneration?
• What are the companies that are currently involved in the development of gene therapy molecules for age-related macular degeneration?
• What are the molecules discontinued from development?
• What are the major regulatory authorities approving drugs in various regions?

Place Purchase Order for this Report@ http://orbisresearch.com/contact/purchase/2099670

Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
Gene therapy for AMD: An insight

PART 05: MAJOR REGULATORY AUTHORITIES
US
Europe
Japan
Australia
China

PART 06: PIPELINE LANDSCAPE

PART 07: COMPARATIVE ANALYSIS
Discovery stage molecules
Pre-clinical stage molecules
Early-stage (Phase I) molecules
Inactive and discontinued molecules

PART 08: INDICATION ANALYSIS

PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)

PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)

PART 11: THERAPEUTIC ASSESSMENT BY TARGET

PART 12: KEY COMPANIES
Active companies: Category and parameters

PART 13: APPENDIX
List of abbreviations

List of Tables:
Exhibit 01: Drug approval process by US FDA
Exhibit 02: Pipeline landscape
Exhibit 03: Pipeline molecules by vendors
Exhibit 04: Pipeline molecules by numbers
Exhibit 05: Pipeline molecules by percentage
Exhibit 06: Overview: Gene therapy for wAMD
Exhibit 07: Overview: GS030
Exhibit 08: Overview: ADVM-022/ADVM-032
Exhibit 09: Overview: Gene therapy for dAMD
Exhibit 10: Overview: A005
Exhibit 11: Overview: A006
Exhibit 12: Overview: RST-001
Exhibit 13: Overview: CERE-120
Exhibit 14: Overview: CERE-140
Exhibit 15: Overview: OXB-201
Exhibit 16: Clinical trials description of OXB-201
Exhibit 17: Overview: RGX-314
Exhibit 18: Clinical trials description of RGX-314
Exhibit 19: Inactive and discontinued molecules by numbers
Exhibit 20: Inactive and discontinued molecules
Exhibit 21: Analysis by disease type
Exhibit 22: Overview of indication
Exhibit 23: Assessment by monotherapy products by stagewise, Continued…

Orbis Research is a single point aid for all your Market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required Market research study for our clients.

Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas - 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: sales@orbisresearch.com

This release was published on openPR.